Business Wire: Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318
MSN: Bristol-Myers Squibb’s New Study on Myelodysplastic Syndrome: What Investors Need to Know
Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert ...
Bristol-Myers Squibb’s New Study on Myelodysplastic Syndrome: What Investors Need to Know
MSN: Bristol-Myers Squibb’s study on oral anticoagulants in elderly NVAF patients: Market insights
Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study. Study Overview: Bristol-Myers Squibb is conducting a study titled ‘A Multicenter Prospective Observational ...
Bristol-Myers Squibb’s study on oral anticoagulants in elderly NVAF patients: Market insights
Business Wire: Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma
Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma
Reuters: Bluebird bio, Bristol-Myers' multiple myeloma therapy shows promise in early study
(Reuters) - Bluebird bio Inc and Bristol-Myers Squibb Co on Monday reported encouraging initial data from an ongoing early-stage study testing their experimental therapy for multiple myeloma in ...
Our optional CE management tool is open for enrollment. Visit us at www.myerscomplete.com to learn more about our cutting-edge cloud-based CE management tool designed to streamline and enrich your staff's learning journey. All current clients are eligible for a complimentary trial of this service.